Open Access
Volume 24, 2017
Article Number 17
Number of page(s) 11
Published online 31 May 2017
  1. Abdel-Mageed WM, Backheet EY, Khalifa AA, Ibraheim ZZ, Ross SA. 2012. Antiparasitic antioxidant phenylpropanoids and iridoid glycosides from Tecoma mollis. Fitoterapia, 83, 500–507. [CrossRef] [PubMed] [Google Scholar]
  2. Acosta-Viana YK, Huchin-Cetz J, Jimenez-Coello M, Guzman-Marin E, Rosales-Encina JL. 2013. Antibody delivery into viable epimastigotes of Trypanosoma cruzi as a tool to study the parasite biology. Advances in Bioscience and Biotechnology, 4, 719–726. [CrossRef] [Google Scholar]
  3. Antúnez MI, Cardoni RL. 2000. IL-12 and IFN-g production, and NK cell activity, in acute and chronic experimental Trypanosoma cruzi infections. Immunology Letters, 71, 103–109. [CrossRef] [PubMed] [Google Scholar]
  4. Aw TY. 1999. Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. American Journal of Clinical Nutrition, 70, 557–565. [CrossRef] [Google Scholar]
  5. Barbabosa-Pliego A, Díaz-Albiter HM, Ochoa-García L, Aparicio-Burgos E, López-Heydeck SM, Velásquez-Ordoñez V. 2009. Trypanosoma cruzi circulating in the southern region of the State of Mexico (Zumpahuacan) are pathogenic: a dog model. American Journal of Tropical Medicine and Hygiene, 81, 390–395. [Google Scholar]
  6. Bonney KM, Engman DM. 2008. Chagas heart disease pathogenesis: one mechanism or many? Current Molecular Medicine, 8, 510–518. [CrossRef] [PubMed] [Google Scholar]
  7. Brener Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Revista do Instituto de Medicina Tropical de São Paulo, 4, 389–396. [Google Scholar]
  8. Cabeza MP, Chambo JG, Laguens RP. 1988. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response. Antimicrobial Agents and Chemotherapy, 32, 241–245. [CrossRef] [PubMed] [Google Scholar]
  9. Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. 2003. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Revista da Sociedade Brasileira de Medicina Tropical, 36, 201–209. [CrossRef] [PubMed] [Google Scholar]
  10. Castro JA. 2000. Contribution of Toxicology to the problem of Chagas disease (American Trypanosomiasis). A year 2000 update. Biomedical and Environmental Sciences, 13, 271–279. [Google Scholar]
  11. Cencig S, Coltel N, Truyens C, Carlier Y. 2012. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or Am Bisome® in mice infected with Trypanosoma cruzi strains. International Journal of Antimicrobial Agents, 40, 527–532. [CrossRef] [PubMed] [Google Scholar]
  12. Chew BP, Mathisona BD, Hayek MG, Massimino S, Reinhart GA, Park JS. 2011. Dietary astaxanthin enhances immune response in dogs. Veterinary Immunology and Immunopathology, 140, 199–206. [CrossRef] [PubMed] [Google Scholar]
  13. Curty LG, Borges JC, Magalhaes CC, Pinheiro de Araújo H, Araujo ZA, Braga do Nascimento S, Machado MC, Rolim-Bernardino AM, De Souza Pereira MC, Cabral BS. 2016. Interactions between 4-aminoquinoline and heme: promising mechanism against Trypanosoma cruzi. International Journal for Parasitology: Drugs and Drug Resistance, 6, 154–164. [CrossRef] [Google Scholar]
  14. Dhiman M, Coronado YA, Vallejo CK, Petersen JR, Ejilemele A, Nuñez S, Zago MP, Spratt H, Garg NJ. 2013. Innate immune responses and antioxidant/oxidant imbalance are major determinants of Human Chagas disease. PLoS Neglected Tropical Diseases, 7(8), e2364. [CrossRef] [PubMed] [Google Scholar]
  15. Díaz-Limay E, Escalante H, Jara AC. 2004. Niveles de parasitemia y alteraciones histopatológicas en Mus musculus BALB/c infectado con Trypanosoma cruzi obtenido de Panstrongylus chinai del Valle Chamán, La Libertad – Perú. Parasitología Latinoamericana, 9, 153–158. [Google Scholar]
  16. Ditrich R, Schibel A, Hoffman I, Mueller A, Beckman M, Cupisti S. 2012. Influence of maternal smoking during pregnancy on oxidant status in amniotic fluid. In Vivo, 26, 813–818. [PubMed] [Google Scholar]
  17. Fassett GR, Coombes JS. 2012. Astaxanthin in cardiovascular health and disease. Molecules, 17, 2030–2048. [CrossRef] [PubMed] [Google Scholar]
  18. Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, Terada H. 2001. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid Astaxanthin. Biochimica et Biophysica Acta – Biomembranes, 1512(2), 251–258. [CrossRef] [Google Scholar]
  19. Graziose R, Rojas-Silva P, Rathinasabapathy T, Dekock C, Grace MH, Poulev A, Lila MA, Smith P, Raskin I. 2012. Antiparasitic compounds from Cornus florida L. with activities against Plasmodium falciparum and Leishmania tarentolae. Journal of Ethnopharmacology, 142, 456–461. [CrossRef] [PubMed] [Google Scholar]
  20. Gupta S, Jian-Jun W, Nisha JG. 2009. Oxidative stress in Chagas Disease. Interdisciplinary Perspectives on Infectious Diseases, 2009, 1–8. [CrossRef] [Google Scholar]
  21. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. 2006. Astaxanthin, a carotenoid with potential in human health and nutrition. Journal of Natural Products, 69, 443–449. [CrossRef] [PubMed] [Google Scholar]
  22. Iwabayashi M, Fujioka N, Keitaro N, Ryo M, Takahashi H, Hibino S, Takahashi Y, Nishikawa K, Nishida M, Yonei Y. 2009. Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden. Anti-Aging Medicine, 6(4), 15–21. [CrossRef] [Google Scholar]
  23. James TN, Rossi MA, Yamamoto S. 2005. Postmortem studies of the intertruncal plexus and cardiac conduction system from patients with Chagas disease who died suddenly. Progress in Cardiovascular Diseases, 47, 258–275. [CrossRef] [PubMed] [Google Scholar]
  24. Kavitha K, Kowshik J, Kiran KK, Basit BB, Nagini S. 2013. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochimica et Biophysica Acta, 1830, 4433–4444. [CrossRef] [PubMed] [Google Scholar]
  25. Kim HY, Koh HK, Doo-Sik K. 2010. Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. International Immunopharmacology, 10, 1560–1572. [CrossRef] [PubMed] [Google Scholar]
  26. Kishimoto Y, Tani M, Uto-Kondo H, Iizuka M, Saita E, Sone H, Kurata H, Kondo K. 2010. Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages. European Journal of Nutrition, 49(2), 119–126. [CrossRef] [PubMed] [Google Scholar]
  27. Kuan-Hung L, Kao-Chang L, Wan-Jung L, Philip-Aloysius T, Thanasekaran J, Joen-Rong S. 2015. Astaxanthin, a carotenoid, stimulates immune responses by enhancing IFN-y and IL-2 Secretion in primary cultured lymphocytes in vitro and ex vivo. International Journal of Molecular Sciences, 17(44), 1–10. [CrossRef] [Google Scholar]
  28. Kuhn RE, Vaughn RT, Herbst GA. 1975. The effect of BCG on the course of experimental Chagas’ disease in mice. International Journal for Parasitology, 5, 557–560. [CrossRef] [PubMed] [Google Scholar]
  29. Leite J, Oliveira A, Lombardi J, Filho J, Chiari E. 2006. Trypanocidal activity of triterpenes from Arrabidaea triplinervia and derivatives. Biological and Pharmaceutical Bulletin, 29, 2307–2309. [CrossRef] [Google Scholar]
  30. Maçao BL, Wilhelm FD, Coury PR, Pereira A, Backes P, Aloisio TM, Silva FT. 2007. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas disease. International Journal of Cardiology, 123, 43–49. [CrossRef] [PubMed] [Google Scholar]
  31. Manning-Cela R, Cortes A, Gonzales-Rey E, Wesley CV, Swindle J, Gonzales A. 2001. LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infection and Immunity, 73(11), 7356–7365. [Google Scholar]
  32. Maya J, Cassels B, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N. 2006. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comparative Biochemistry and Physiology, 146, 601–620. [CrossRef] [PubMed] [Google Scholar]
  33. Meyers PS, Bligh D. 1981. Characterization of astaxanthin pigments from heat-processed crawfish waste. Journal of Agricultural and Food Chemistry, 29(3), 505–508. [CrossRef] [PubMed] [Google Scholar]
  34. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. 2010. Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Research, 30, 2721–2726. [PubMed] [Google Scholar]
  35. National Academic of Science. 2011. Guide for the Care and Use of Laboratory Animals, 8th edn.. National Academic Press: Washington DC. [Google Scholar]
  36. Navideh A, Chin PT. 2013. Effects of selected polysorbate and sucrose ester emulsifiers on the physicochemical properties of astaxanthin nanodispersions. Molecules, 18, 768–777. [CrossRef] [PubMed] [Google Scholar]
  37. NORMA Oficial Mexicana NOM-062-ZOO-1995. 1995. Especificaciones y característica zoosanitarias para el transporte de animales, sus productos y subproductos, productos químicos, farmacéuticos, biológicos y alimenticios para uso en animales o consumo por éstos. Mexico City, Mexico: Diario Oficial de la Federación. [Google Scholar]
  38. NORMA Oficial Mexicana NOM-062-ZOO-1999. 1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. Mexico City, Mexico: Diario Oficial de la Federación. [Google Scholar]
  39. Okai Y, Higashi-Okai K. 1996. Possible immunomodulating activities of carotenoids in in vitro cell culture experiments. International Journal of Immunopharmacology, 18, 753–758. [CrossRef] [PubMed] [Google Scholar]
  40. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. 2010. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & Metabolism, 7(18), 1–10. [CrossRef] [PubMed] [Google Scholar]
  41. Pereira AL, Rocha-Rodriguez D, Costa Da Cunha E, Dos-Reis MA, Antúnez V. 2002. Morphometric study of the spleen in chronic Chagas disease. American Journal of Tropical Medicine and Hygiene, 66(4), 401–403. [CrossRef] [Google Scholar]
  42. Ribeiro MC, Coury PR, Sinfroni FM, Bennedetti PE, Monguillhott DE, Silva FT, Oliveira-Silva D, Colepicolo P, Wilhelm FD. 2010. Antioxidant therapy attenuates oxidative insult caused by benzonidazole in chronic Chagas heart disease. International Journal of Cardiology, 145, 27–33. [CrossRef] [PubMed] [Google Scholar]
  43. Rolón M, Vega C, Escario JA, Gómez-Barrio A. 2006. Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitology Research, 99, 103–107. [CrossRef] [PubMed] [Google Scholar]
  44. Rose S, Misharin A, Perlman H. 2012. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A, 81(4), 343–350. [CrossRef] [PubMed] [Google Scholar]
  45. Rowland CE, Sibley-Phillips S. 1984. Bone marrow eosinophil levels in Trypanosoma cruzi infected mice. Journal of Parasitology, 70(5), 819–820. [CrossRef] [Google Scholar]
  46. Silveira AC, Dias JC. 2011. The control of vectorial transmission. Revista da Sociedade Brasileira de Medicina Tropical, 44(2), 52–63. [CrossRef] [PubMed] [Google Scholar]
  47. Silveira AC. 2011. New challenges and the future of control. Revista da Sociedade Brasileira de Medicina Tropical, 44(2), 122–124. [CrossRef] [PubMed] [Google Scholar]
  48. Uchiyama N, Kabututu Z, Kubata B, Kiuchi F, Ito M, Nakajima-Shimada J. 2005. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme. Antimicrobial Agents and Chemotherapy, 49(12), 5123–5126. [CrossRef] [PubMed] [Google Scholar]
  49. Ukachi EI, Igoli JO, Onyiriuka SO, Ejele AE, Ogukwe CE, Ayuk AA, Elemo GN, Gray AI. 2015. Antitrypanosomal and antioxidant activities of Moringa oleifera lam leaf extracts. Journal of Pharmaceutical, Chemical and Biological Sciences, 3(1), 17–23. [Google Scholar]
  50. Viotti R, Vigliano C, Lococo B, Álvarez M, Petti M, Bertochi G. 2009. Side effects of benznidazole as treatment of Chagas disease: fears and realities. Expert Review of Anti-infective Therapy, 14(7), 157–163. [CrossRef] [Google Scholar]
  51. Wen JJ, Gupta S, Guan Z, Dhiman M, Condon D, Lui C, Garg NJ. 2010. Phenyl-α-tert-butyl-nitrone and benzonidazole treatment controlled the mitochondrial oxidative stress and evolution of cardiomyopathy in chronic chagasic rats. Journal of the American College of Cardiology, 55(22), 2499–2508. [CrossRef] [PubMed] [Google Scholar]
  52. WHO. 2017. Chagas disease (American trypanosomiasis). [Google Scholar]
  53. Zacks MA, Wen JJ, Vyatkina G, Bhatia V, Garg N. 2005. An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. Annals of the Brazilian Academy of Sciences, 77(4), 695–715. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.